The Effects of Synbiotic Supplementation on Glycemic Status, Lipid Profile, and Biomarkers of Oxidative Stress in Type 1 Diabetic Patients. A Placebo-Controlled, Double-Blind, Randomized Clinical Trial

• Published in: Diabetes, metabolic syndrome and obesity metabolic syndrome and obesity, 2020-01, Vol.13, p.607-617
• Main Authors: Zare Javid, Ahmad, Aminzadeh, Majid, Haghighi-Zadeh, Mohammad Hosein, Jamalvandi, Mona
• Format: Article
• Language: English
• Subjects: glycemic status; inflammation; lipid profile; Original Research; synbiotic; type 1 diabetes mellitus
• ISSN: 1178-7007; 1178-7007
• DOI: 10.2147/DMSO.S238867

The aim of the present study was to evaluate the effects of synbiotic on glycemic status, lipid profile, and biomarkers of oxidative stress in type 1 diabetes mellitus (T1DM) patients. In this double-blind clinical trial, 50 T1DM patients were randomly allocated to intervention (n = 25) and control (n = 25) groups and received either synbiotic powder ( GBI-30 (probiotic), maltodextrin and fructooligosaccharide (prebiotic)) or placebo 2 g per day for 8 weeks. Fasting blood samples were collected before and after the intervention to measure fasting blood glucose (FBG), insulin concentration, hemoglobin A1c (HbA1c), lipid profile, and biomarkers of oxidative stress such as total antioxidant capacity (TAC) and hs-C-reactive protein (hs-CRP). Supplementation with synbiotic resulted in a significant decrease in the mean serum levels of HbA1c and hs-CRP ( = 0.01 and = 0.004, respectively), and marginally significant decrease in FBG ( = 0.05) in the intervention group post- intervention. Also, the mean changes of FBG and hs-CRP were significantly lower in the intervention group compared with the control group ( = 0.03 and = 0.005, respectively). There were no significant changes found in lipid profile in intervention group post-intervention ( ≥ 0.05). The mean serum levels of insulin and TAC were significantly increased in the intervention group post-intervention ( = 0.001). There was a significant increase in the mean changes of TAC ( = 0.005) in the intervention group compared with the control group. The 8-week synbiotic supplementation in T1DM patients may be effective in improvement of FBG, HbA1c, insulin, hs-CRP, and TAC.